Go Back   Science Forums Biology Forum Molecular Biology Forum Physics Chemistry Forum > General Science Forums > Biology Forum
Register Search Today's Posts Mark Forums Read

Biology Forum Biology Forums. Ask questions and discuss the study of Biology. If you have Biology questions from your homework ask them here!


Elotuzumab can make more than 90% of myeloma patients benefit

Elotuzumab can make more than 90% of myeloma patients benefit - Biology Forum

Elotuzumab can make more than 90% of myeloma patients benefit - Biology Forums. Ask questions and discuss the study of Biology. If you have Biology questions from your homework ask them here!


Reply
 
LinkBack Thread Tools Display Modes
  #1  
Old 07-05-2012, 02:27 AM
UnSubscribed Vendor Advertiser
Points: 466, Level: 9 Points: 466, Level: 9 Points: 466, Level: 9
Activity: 0% Activity: 0% Activity: 0%
 
Join Date: May 2012
Posts: 40
Thanks: 1
Thanked 0 Times in 0 Posts
Default Elotuzumab can make more than 90% of myeloma patients benefit



From Chicago: elotuzumab is a monoclonal antibody, is basically only in the [Only registered users see links. ] myeloma cells. The researchers say: even if these patients with other medical therapy, the disease continued development; elotuzumab treatment, these patients more than 90% of the treatment of the objective.By Philippe of Moreau's message: a Phase II clinical trials, after a follow-up of 17.2 months, using the 10 mg dose of elotuzumab therapy patients still do not get the MBL2 median progression-free survival. MD Philippe of Moreau, France at Nance City University Department of Hematology, Hotel-Dieu Hospital Director."In phase III clinical studies are still using the 10 mg dose of Moreau in the oral speech of the American Society of Clinical Oncology annual meeting of this introduction. This Phase II clinical study tested the 20 mg dose; found that the dose group is greater than the side MBP effects of the 10 mg dose group, a lower efficacy. In a conference on the treatment of multiple myeloma therapy, he reported that: the trial of high dose group median progression-free survival was 18.6 months.Patients recruited in this study used at least in the previous first-line drug therapy, the disease progress in at least 1; during elotuzumab, lenalidomide (lenalidomide,) and dexamethasone (of dexamethasone) before MCAM treatment, only been a first-line treatment of patients, 91% of patients achieved the target response.In addition to the observed therapeutic effect (effectiveness), Phase II clinical research study carefully the safety of the drug. Two-dose group, has more than half of the patients had diarrhea, muscle cramps and constipation, but only less than 10% of patients had 3 to 4 times side effects. Patients taking 10 mg dose is approximately 1/3 of the MCEE back pain, 22% in the high dose group throughout the study, only 2 patients with 3 to 4 back pain.

Rafael Fonseca, said: "Bone is a big problem for patients with bone tumors." The M.D. Rafael Fonseca, the medical director of the Mayo Clinic in Scottsdale, Arizona, USA. He said: "at least 70% of patients with myeloma bone disease; we really do not have good biological markers for diagnosis. The event of a fracture, a bit like archeology, we are checking the ruins."Moreau prompt: In the phase I clinical dose range test, 82% of the 28 patients reached the target reaction. In that study, the dose is not yet high reach dose-limiting toxicity; did not reach the median progression-free survival; did not reach the maximum tolerated dose. Phase II clinical study was designed to exceed these numbers - 10 mg dose has been completed this initiative, 92% of patients had a target reaction.The Phase II clinical study recruited 73 patients. 30 days for a course, 1,8,15,22 days in each course of treatment, these patients received 10 mg / kg or 20 mg / kg elotuzumab treatment. All treated patients, plus a daily serving of 25 mg of lenalidomide (lenalidomide,), plus a week to service of 40 mg dexamethasone (dexamethasone). Until the course of the patient's progress or produce unacceptable toxicity, stop the treatment process. Dexamethasone the elotuzumab treatment before administration. Qualified patient refers to patients with recurrent or multiple myeloma, measurable M protein, kidney function can accept.Moreau and colleagues recruited 36 patients recruited in the 10 mg group, 37 patients recruited in the 20 mg group. The median age of these patients was 63 years elapsed from diagnosis to recruit about 4.5 years; 55% of the treatment after 2 or more times; 82% had stem cell transplants; 62% before Sally polyamine treatment.Moreau said that half of patients stop treatment - 12 because of disease progression, two because of side effects; in the 20 mg group, 65% of patients stopped treatment: 10 mg group - 12 because of disease progression, is because of side effects.
Reply With Quote
Reply

Tags
90% , benefit , elotuzumab , make , mbl1 , mbl2 , mbp , mcam , mcee , myeloma , patients


Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Trackbacks are On
Pingbacks are On
Refbacks are On

Forum Jump

Similar Threads
Thread Thread Starter Forum Replies Last Post
>>>> MAKE RADIO <<<< Tania Guthrie Forum Physik 0 09-23-2009 04:43 PM
Politics And Cannibalism? Introducing The Dourties, Chelsea, Bill, Hillary, Barrack Obama, George Bush, Jr., And All Of Capital Hill! jon_johnfrancisayres@yahoo.com Microbiology Forum 0 10-06-2007 05:59 AM
Cosa e' un virus ? G. Paolo Forum Biologia 182 05-29-2006 06:33 PM
All customers PAY YOU IN CASH !!! Tia Protocols and Methods Forum 0 11-19-2005 06:57 PM


All times are GMT. The time now is 01:10 AM.


Powered by vBulletin® Version 3.8.4
Copyright ©2000 - 2014, Jelsoft Enterprises Ltd.
Copyright 2005 - 2012 Molecular Station | All Rights Reserved
Page generated in 0.14813 seconds with 16 queries